Association of baseline CEA, VEGF, and soluble VEGF receptor-2 with treatment outcomes in two randomized phase III trials of cediranib in metastatic colorectal cancer (mCRC).Hans‐Joachim Schmoll, J.M. Jürgensmeier, Laura A. Pike et al.|Journal of Clinical Oncology|2011Cited by 7
Exploration of the effect of treatment to progression with the VEGF signaling inhibitor cediranib (CED) plus chemotherapy (CT) on the results of the HORIZON (HZ) II trial in first-line metastatic colorectal cancer.Anitra Fielding, Jane Robertson, P. M. Hoff et al.|Journal of Clinical Oncology|2011Cited by 3
Use of KRAS mutation status to predict clinical outcomes in patients with metastatic colorectal cancer (mCRC) treated with the VEGF signaling inhibitor cediranib.J.M. Jürgensmeier, Jeff Smith, P. M. Hoff et al.|Journal of Clinical Oncology|2011Cited by 3
Application of adaptive study designs: Phase II and III results from the cediranib (CED) HORIZON (HZ) II and III studies.D. Wilson, A Stone, Jane Robertson et al.|Journal of Clinical Oncology|2011Cited by 2